JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies

  NCT04001517

  Condition:   Dementia With Lewy Bodies (DLB)
  Intervention:   Drug: Neflamapimod
  Sponsors:   EIP Pharma Inc;   Worldwide Clinical Trials
  Recruiting
• AGN-241751 in the Treatment of Major Depressive Disorder

  NCT03726658

  Condition:   Major Depressive Disorder
  Interventions:   Drug: AGN-241751;   Drug: Placebo
  Sponsor:   Naurex, Inc, an affiliate of Allergan plc
  Recruiting
• Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms

  NCT00443274

  Condition:   Breast Implant
  Interventions:   Other: NBIR Placeholder;   Device: 410 Arm;   Device: BIFs
  Sponsor:   Allergan
  Recruiting
• Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967

  Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

  NCT02465060

  Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
  Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

  NCT02224781

  Conditions:   BRAF NP_004324.2:p.V600X;   Metastatic Melanoma;   Progressive Disease;   Recurrent Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma
  Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

  NCT02201992

  Conditions:   ALK Gene Rearrangement;   ALK Gene Translocation;   ALK Positive;   Stage IB Non-Small Cell Lung Carcinoma AJCC v7;   Stage II Non-Small Cell Lung Cancer AJCC v7;   Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Laboratory Biomarker Analysis
  Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
  Recruiting
• Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738

  Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

  NCT02193282

  Conditions:   ALK Gene Rearrangement;   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

  NCT01901094

  Conditions:   Stage II Breast Cancer;   Stage IIIA Breast Cancer
  Interventions:   Procedure: Axillary Lymph Node Dissection (ALND);   Radiation: Nodal Radiation Therapy;   Radiation: Axillary Radiation Therapy
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery

  NCT01101451

  Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Stage I Cervical Cancer AJCC v6 and v7;   Stage IA Cervical Cancer AJCC v6 and v7;   Stage IB Cervical Cancer AJCC v6 and v7;   Stage IIA Cervical Cancer AJCC v7
  Interventions:   Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia

  NCT02832037

  Condition:   Schizophrenia
  Interventions:   Drug: BI 425809 dose 1;   Drug: BI 425809 dose 2;   Drug: BI 425809 dose 3;   Drug: BI 425809 dose 4;   Drug: Placebo
  Sponsor:   Boehringer Ingelheim
  Recruiting
• Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder

  NCT04044664

  Condition:   Post-Traumatic Stress Disorder
  Interventions:   Drug: Placebo oral capsule;   Drug: NYX-783
  Sponsors:   Aptinyx;   Premier Research Group plc;   Massachusetts General Hospital
  Recruiting
• ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis

  NCT03923478

  Conditions:   Ulcerative Colitis Chronic Mild;   Ulcerative Colitis Chronic Moderate
  Interventions:   Drug: ABI-M201;   Drug: Placebo
  Sponsors:   Assembly Biosciences;   Allergan
  Recruiting
• Acute Treatment Trial in Adult Subjects With Migraines

  NCT03872453

  Condition:   Migraine
  Interventions:   Drug: BHV3500 10mg;   Drug: BHV3500 20mg;   Drug: BHV3500 5mg;   Drug: BHV3500 matching placebo;   Device: Intranasal Aptar Pharma Unit Dose System
  Sponsor:   Biohaven Pharmaceuticals, Inc.
  Recruiting
• A Study to Evaluate SAGE-217 in Adult Subjects With Major Depressive Disorder

  NCT03864614

  Condition:   Major Depressive Disorder
  Intervention:   Drug: SAGE-217
  Sponsor:   Sage Therapeutics
  Recruiting
• Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine

  NCT03855137

  Condition:   Chronic Migraine
  Interventions:   Drug: Atogepant 30 mg;   Drug: Atogepant 60 mg;   Drug: Placebo
  Sponsor:   Allergan
  Recruiting
• Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

  NCT03851445

  Condition:   Previously Treated Non-Small Cell Lung Cancer
  Intervention:   Drug: Screening Platform
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Randomized Trial of Adult Subjects With Generalized Anxiety Disorder

  NCT03829241

  Condition:   Generalized Anxiety Disorder
  Interventions:   Drug: Troriluzole;   Drug: Placebo
  Sponsor:   Biohaven Pharmaceuticals, Inc.
  Recruiting
• GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease

  NCT03823404

  Condition:   Alzheimer Disease
  Interventions:   Drug: COR388 capsule;   Drug: Placebo capsule
  Sponsor:   Cortexyme Inc.
  Recruiting
• An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis

  NCT03777436

  Condition:   Psoriasis
  Interventions:   Drug: Apremilast;   Other: Placebo
  Sponsor:   Celgene
  Recruiting
• To Evaluate the Safety and Tolerability of Atogepant 10mg, 30 mg and 60 mg Once a Day for the Prevention of Migraine in Participants With Episodic Migraine

  NCT03777059

  Condition:   Episodic Migraine
  Interventions:   Drug: Atogepant 30 mg;   Drug: Atogepant 60 mg;   Drug: Placebo;   Drug: Atogepant 10 mg
  Sponsor:   Allergan
  Recruiting
• Phase II Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Non-small Cell Lung Cancer (NSCLC)

  NCT03739710

  Condition:   Neoplasms
  Interventions:   Drug: Docetaxel;   Drug: GSK3359609 (ICOS Agonist)
  Sponsor:   GlaxoSmithKline
  Recruiting
• Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type

  NCT03721705

  Conditions:   Alzheimer Disease;   Cognitive Dysfunction;   Mild Cognitive Impairment;   Mild Dementia;   Cognitive Decline;   Dementia, Alzheimer Type
  Intervention:   Device: Renew NCP-5
  Sponsors:   Renew Research, LLC;   KAI Research
  Recruiting
• Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia

  NCT03701282

  Conditions:   CCND1/IGHG1 Fusion Negative;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   t(11;14) Negative
  Interventions:   Drug: Ibrutinib;   Biological: Obinutuzumab;   Other: Quality-of-Life Assessment;   Drug: Venetoclax
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Study of Lasmiditan (LY573144) Over Four Migraine Attacks

  NCT03670810

  Condition:   Migraine
  Interventions:   Drug: Lasmiditan;   Drug: Placebo
  Sponsor:   Eli Lilly and Company
  Recruiting
• Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer

  NCT03633006

  Condition:   Lung Cancer (Diagnosis)
  Intervention:   Other: Blood Sample Collection
  Sponsor:   Exact Sciences Corporation
  Recruiting
• A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors

  NCT03561090

  Condition:   Gastroesophageal Reflux Disease (GERD)
  Interventions:   Drug: IW-3718;   Drug: placebo
  Sponsor:   Ironwood Pharmaceuticals, Inc.
  Recruiting
• RESPOND TO PREVENT: Stepwise Pharmacy Naloxone Study

  NCT03545321

  Conditions:   Pharmacies;   Opioid Use;   Patient Safety
  Intervention:   Behavioral: MOON+
  Sponsors:   Boston Medical Center;   Comagine Health;   Oregon Health and Science University;   University of Rhode Island;   University of Washington;   National Institute on Drug Abuse (NIDA)
  Recruiting
• A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE )

  NCT03518034

  Conditions:   Hypogonadism;   Cardiovascular Diseases
  Interventions:   Drug: Testosterone;   Drug: Placebo
  Sponsors:   AbbVie;   Acerus Pharmaceuticals Corporation;   Allergan Sales, LLC;   Endo Pharmaceuticals;   Upsher-Smith Laboratories
  Recruiting
• A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension

  NCT03504917

  Condition:   Autism Spectrum Disorder
  Interventions:   Drug: Balovaptan;   Drug: Placebo
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year

  NCT03464136

  Condition:   Crohn Disease
  Interventions:   Biological: Placebo for Ustekinumab;   Biological: Placebo for Adalimumab;   Biological: Ustekinumab (6 mg/kg);   Biological: Ustekinumab (90 mg);   Biological: Adalimumab (40 mg)
  Sponsor:   Janssen Scientific Affairs, LLC
  Recruiting
• Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

  NCT03444870

  Condition:   Alzheimer Disease
  Interventions:   Drug: Gantenerumab;   Drug: Placebo
  Sponsor:   Hoffmann-La Roche
  Recruiting
• S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer

  NCT03418961

  Conditions:   Cardiotoxicity;   HER2/Neu Positive;   Metastatic Malignant Neoplasm in the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Drug: Carvedilol;   Other: Laboratory Biomarker Analysis;   Other: Patient Observation
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Project IMPACT Immunizations (IMProving America's Communities Together) Scaled Demonstration

  NCT03372967

  Condition:   Influenza
  Interventions:   Biological: Vaccine administration by a pharmacist;   Behavioral: Unmet vaccination needs identified and met;   Behavioral: Vaccination forecast review and patient education
  Sponsor:   American Pharmacists Association Foundation
  Recruiting
• A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies

  NCT03345849

  Condition:   Crohn's Disease
  Interventions:   Drug: Upadacitinib;   Drug: Placebo for Upadacitinib
  Sponsor:   AbbVie
  Recruiting
• A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

  NCT03345836

  Condition:   Crohn's Disease
  Interventions:   Other: Matching placebo for upadacitinib;   Drug: upadacitinib
  Sponsor:   AbbVie
  Recruiting
• Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC

  NCT03326674

  Condition:   Breast Cancer
  Interventions:   Drug: Tesetaxel and Capecitabine;   Drug: Capecitabine
  Sponsor:   Odonate Therapeutics, Inc.
  Recruiting
• A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)

  NCT03305809

  Condition:   Lewy Body Dementia
  Interventions:   Drug: LY3154207;   Drug: Placebo
  Sponsor:   Eli Lilly and Company
  Recruiting
• BHV-4157 in Adult Subjects With Obsessive Compulsive Disorder

  NCT03299166

  Condition:   Obsessive-Compulsive Disorder
  Interventions:   Drug: BHV-4157;   Drug: Placebo
  Sponsor:   Biohaven Pharmaceuticals, Inc.
  Recruiting
• Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

  NCT03244384

  Conditions:   Stage II Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
  Interventions:   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)

  NCT03188185

  Condition:   Major Depressive Disorder
  Interventions:   Drug: ALKS 5461;   Drug: ALKS 5461 Placebo
  Sponsor:   Alkermes, Inc.
  Recruiting
• Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids

  NCT03070899

  Conditions:   Uterine Fibroids;   Heavy Menstrual Bleeding
  Interventions:   Drug: Placebo + Placebo Add-back;   Drug: OBE2109 + Placebo Add-back;   Drug: OBE2109 + Add-back
  Sponsor:   ObsEva SA
  Recruiting
• Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery

  NCT03033576

  Conditions:   Advanced Melanoma;   Melanoma of Unknown Primary;   Mucosal Melanoma;   Refractory Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma;   Unresectable Melanoma
  Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

  NCT02993406

  Conditions:   Cardiovascular Diseases;   Statin Adverse Reaction
  Interventions:   Drug: Bempedoic acid 180 mg tablet;   Drug: Matching placebo tablet
  Sponsors:   Esperion Therapeutics;   The Cleveland Clinic
  Recruiting
• Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

  NCT02973789

  Condition:   Nonsmall Cell Lung Cancer
  Interventions:   Device: NovoTTF-100L;   Drug: Immune checkpoint inhibitors or docetaxel
  Sponsor:   NovoCure Ltd.
  Recruiting
• Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

  NCT02927249

  Condition:   Node Positive HER2 Negative Breast Cancer
  Interventions:   Other: Placebo;   Drug: Aspirin
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
  Recruiting
• Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS

  NCT02926911

  Conditions:   DCIS;   Ductal Carcinoma in Situ
  Interventions:   Other: Guideline Concordant Care;   Other: Active Surveillance
  Sponsors:   Alliance Foundation Trials, LLC.;   Patient-Centered Outcomes Research Institute;   Duke University;   Dana-Farber Cancer Institute;   M.D. Anderson Cancer Center;   New York University;   Washington University School of Medicine
  Recruiting
• Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

  NCT02924727

  Condition:   Acute Myocardial Infarction
  Interventions:   Drug: LCZ696 (sacubitril/valsartan);   Drug: Ramipril;   Drug: Placebo of LCZ696;   Drug: Placebo of ramipril;   Drug: Valsartan;   Drug: Placebo of valsartan
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

  NCT02921256

  Conditions:   Rectal Adenocarcinoma;   Stage II Rectal Cancer AJCC v7;   Stage III Rectal Cancer AJCC v7
  Interventions:   Drug: Capecitabine;   Drug: Fluorouracil;   Radiation: Intensity-Modulated Radiation Therapy;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Biological: Pembrolizumab;   Drug: Veliparib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes

  NCT02856581

  Condition:   Lung Carcinoma
  Interventions:   Drug: Varenicline;   Drug: Placebo;   Other: Tobacco Cessation Counseling
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Pfizer
  Recruiting
• Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

  NCT02834013

  Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Angiosarcoma;   Apocrine Neoplasm;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Basal Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cervical Clear Cell Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Extramammary Paget Disease;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gallbladder Carcinoma;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Gestational Trophoblastic Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   PEComa;   Peritoneal Mesothelioma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Solid Neoplasm;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Somatic-Type Malignancy;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
  Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826

  Condition:   Breast Carcinoma
  Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
  Recruiting
• S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

  NCT02562716

  Conditions:   Pancreatic Adenocarcinoma;   Resectable Pancreatic Carcinoma
  Interventions:   Drug: Fluorouracil;   Drug: Gemcitabine Hydrochloride;   Drug: Irinotecan Hydrochloride;   Drug: Oxaliplatin;   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;   Procedure: Pancreatectomy
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer

  NCT02466971

  Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Stage IB2 Cervical Cancer AJCC v6 and v7;   Stage II Cervical Cancer AJCC v7;   Stage II Vaginal Cancer AJCC v6 and v7;   Stage IIA Cervical Cancer AJCC v7;   Stage IIB Cervical Cancer AJCC v6 and v7;   Stage III Vaginal Cancer AJCC v6 and v7;   Stage IIIB Cervical Cancer AJCC v6 and v7;   Stage IVA Cervical Cancer AJCC v6 and v7;   Stage IVA Vaginal Cancer AJCC v6 and v7;   Vaginal Adenocarcinoma;   Vaginal Adenosquamous Carcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
  Interventions:   Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Internal Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Radiation: Radiation Therapy;   Drug: Triapine
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer

  NCT02177695

  Condition:   Bladder Cancer
  Interventions:   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Methotrexate;   Drug: Vinblastine;   Drug: Doxorubicin;   Drug: Filgrastim
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies

  NCT02118584

  Condition:   Ulcerative Colitis
  Intervention:   Drug: Etrolizumab
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial

  NCT02089217

  Condition:   Carotid Stenosis
  Interventions:   Procedure: Carotid endarterectomy (CEA);   Device: Carotid Stenting (CAS);   Other: Intensive Medical Management - no CEA;   Other: Intensive Medical Management - no CAS
  Sponsors:   Thomas G. Brott, M.D.;   National Institute of Neurological Disorders and Stroke (NINDS)
  Recruiting
• Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

  NCT02003222

  Conditions:   Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative;   BCR/ABL1 Fusion Protein Negative;   Untreated Adult Acute Lymphoblastic Leukemia
  Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
  Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• A Study to Evaluate Scales for Repetitive and Restricted Behaviors in Children, Adolescents, and Adults With Autism Spectrum Disorder (ASD)

  NCT03611075

  Condition:   Autism Spectrum Disorder
  Intervention:   Other: No Intervention
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus Aged 10 to Below 18 Years Old

  NCT03199053

  Condition:   Diabetes Mellitus, Type 2
  Interventions:   Drug: Dapagliflozin;   Drug: Saxagliptin;   Drug: Placebo
  Sponsor:   AstraZeneca
  Recruiting
• S0820, Adenoma and Second Primary Prevention Trial

  NCT01349881

  Condition:   Colorectal Neoplasms
  Interventions:   Drug: Eflornithine placebo & sulindac placebo;   Drug: eflornithine & sulindac placebo;   Drug: Eflornithine placebo & sulindac;   Drug: Eflornithine plus sulindac
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Cancer Prevention Pharmaceuticals, Inc.
  Recruiting
• Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

  NCT00632853

  Condition:   Lung Cancer
  Interventions:   Radiation: Standard Radiation Dose Therapy;   Drug: cisplatin;   Drug: etoposide;   Radiation: High Radiation Dose Therapy;   Drug: carboplatin
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study

  NCT03691649

  Condition:   Glaucoma and Ocular Hypertension
  Interventions:   Drug: DE-117 Ophthalmic Solution;   Drug: Timolol Maleate Ophthalmic Solution 0.5%
  Sponsor:   Santen Inc.
  Recruiting
• A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03653026

  Condition:   Ulcerative Colitis (UC)
  Interventions:   Drug: Upadacitinib (ABT-494);   Drug: Placebo
  Sponsor:   AbbVie
  Recruiting
• Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma

  NCT03347279

  Condition:   Asthma
  Interventions:   Biological: Experimental: Tezepelumab;   Other: Placebo
  Sponsors:   AstraZeneca;   Amgen
  Recruiting
• A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease

  NCT03105128

  Condition:   Crohn's Disease
  Interventions:   Drug: placebo for risankizumab;   Drug: risankizumab IV;   Drug: risankizumab SC
  Sponsor:   AbbVie
  Recruiting
• A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

  NCT03104413

  Condition:   Crohn's Disease
  Interventions:   Drug: placebo for risankizumab IV;   Drug: risankizumab SC;   Drug: risankizumab IV
  Sponsor:   AbbVie
  Recruiting
• A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT02819635

  Condition:   Ulcerative Colitis (UC)
  Interventions:   Drug: Placebo;   Drug: Updacitinib (ABT-494)
  Sponsor:   AbbVie
  Recruiting